The increased Akt activation by lenalidomide treated XBP1-CTL during tumor recognition may be associated with costimulatory signaling molecule CD28, a critical regulator of T cell proliferation and important for T cell activation and effector cells development [56,57]. This evidence concerns the gene XBP1 and neoplasm.